No Data
Express News | SpringWorks Therapeutics Inc - Nirogacestat Shows Further Tumor Size Reductions and Increased Orr
Express News | SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data From Phase 3 Defi Trial of Ogsiveo® (Nirogacestat) in Adults With Desmoid Tumors to Be Presented at the Connective Tissue Oncology Society (Ctos) 2024 Annual Meeting
Earnings Preview: SWTX to Report Financial Results Pre-market on November 12
$SpringWorks Therapeutics(SWTX.US)$ is scheduled to release its financial results pre-market on November 12 ET. Earnings PreviewAnalysts estimate $SpringWorks Therapeutics(SWTX.US)$ to post revenue
SpringWorks Therapeutics to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Good Position To Deliver On Growth Plans
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
No Data
No Data